PMID- 26474563
OWN - NLM
STAT- MEDLINE
DCOM- 20160707
LR  - 20231111
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 14
DP  - 2015 Oct 17
TI  - Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) 
      inhibitor, in diabetes mellitus.
PG  - 142
LID - 10.1186/s12933-015-0297-x [doi]
LID - 142
AB  - Although antidiabetic agents have been developed to target one or more of the 
      core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve 
      glycemic goals. Inhibition of the sodium-glucose cotransporter 2 (SGLT2) induces 
      glycosuria, reduces glucose toxicity and improves insulin sensitivity and beta-cell 
      function. As the mechanism of action of SGLT2 inhibitors is different from other 
      agents and completely insulin-independent, the use of these drugs might 
      potentially be efficacious alone or in combination with any other antidiabetic 
      drug, including insulin. Dapagliflozin is a highly selective and reversible SGLT2 
      inhibitor approved for use in adult patients with T2DM as monotherapy in patients 
      intolerant of metformin or as adjunctive therapy in patients inadequately 
      controlled on existing antidiabetic medications, including insulin. A literature 
      search conducted using PubMed identified key publications related to the use of 
      dapagliflozin in the treatment of patients with diabetes mellitus. No date limits 
      were applied. This review focuses on the safety and efficacy of this SGLT2 
      inhibitor. Dapagliflozin produces dose-related reductions in glycosylated 
      hemoglobin (HbA1c) as monotherapy and as add-on to other antidiabetic agents, 
      with significant reductions in body weight. Hypoglycemia is uncommon. Preliminary 
      data from a phase 2 pharmacokinetic/pharmacodynamic study suggest that 
      dapagliflozin may also improve glycemic control in patients with type 1 diabetes 
      mellitus. Clinical trials published to date show that dapagliflozin is safe and 
      effective as monotherapy or as an add-on to insulin or oral antidiabetic agents 
      in patients with T2DM.
FAU - Fioretto, Paola
AU  - Fioretto P
AD  - Department of Medicine, University of Padua, Via Giustiniani 2, 35128, Padua, 
      Italy. paola.fioretto@unipd.it.
FAU - Giaccari, Andrea
AU  - Giaccari A
AD  - EndoMetabolic Diseases Unit, Policlinico Gemelli, Universita Cattolica del Sacro 
      Cuore, Largo A. Gemelli 8, 00168, Rome, Italy. giaccari@rm.unicatt.it.
FAU - Sesti, Giorgio
AU  - Sesti G
AD  - Department of Medical and Surgical Sciences, University Magna-Graecia of 
      Catanzaro, Viale Europa, 88100, Catanzaro, Italy. sesti@unicz.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151017
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Diabetes Mellitus, Type 1/*drug therapy/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Drug Therapy, Combination
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors
MH  - Treatment Outcome
PMC - PMC4609166
EDAT- 2015/10/18 06:00
MHDA- 2016/07/09 06:00
PMCR- 2015/10/17
CRDT- 2015/10/18 06:00
PHST- 2015/07/28 00:00 [received]
PHST- 2015/09/25 00:00 [accepted]
PHST- 2015/10/18 06:00 [entrez]
PHST- 2015/10/18 06:00 [pubmed]
PHST- 2016/07/09 06:00 [medline]
PHST- 2015/10/17 00:00 [pmc-release]
AID - 10.1186/s12933-015-0297-x [pii]
AID - 297 [pii]
AID - 10.1186/s12933-015-0297-x [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x.